|
|
|
| Anastrozole therapy in postmenopausal breast cancer secondary to osteoporosis |
| LI Wen-huan, ZHOU Zhuo-hui |
| Department of Breast and Thyroid Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, Hubei, China |
|
|
|
|
Abstract Objective To collect postmenopausal breast cancer patients taking anastrozole after the relevant clinical indicators, The predictive model was established to evaluate the predictive value of secondary osteoporosis (OP), and then verify its applicability. Methods Continuity included in the period from May 2013 to April 2014 in Wuhan City Center Hospital treated with anastrozole endocrine therapy for postmenopausal breast cancer patients for the study of the cohort, the clinical data were collected and followed for a follow-up of 36 months to confirm prognosis. According to the follow-up results predictive secondary risk of OP risk indicators, and analyze the secondary OP time window to verify the applicability of the prediction model. Results The final collection of 252 cases of breast cancer patients in line with the clinical trial requirements, of which 12 patients were lost, 75 patients secondary to OP, 165 patients in the follow-up period of bone mineral density normal or relatively normal. Cox regression analysis showed that the independent influencing factors of adjuvant OP in patients with postmenopausal breast cancer were determined by the time of menopause, the time of taking anastrozole, the time of bisphosphonates, the contents of alkaline phosphates (ALP) Among them, menopause time and taking anastrozole time as a risk factor, taking bisphosphonates time and ALP content as protective factors; taking anastrozole time≥3.07 years, taking bisphosphonates time <1. 878 years of patients, secondary OP time window shorter, the critical value of a significant evaluation of efficacy. Conclusion Menopause time, taking anastrozole time, taking bisphosphonates time, ALP content is anastrozole in the treatment of postmenopausal breast cancer secondary OP independent factors, and taking anastrozole time≥3.07 years, taking bisphosphonates time <1.788 years to measure the disease secondary to the patient's time nod
|
|
|
|
|
|
| [1] |
1LIU Yong-bo，2，3DENG Li， 1GUO Yi-hui，1LI Yan-ping. Atg13 gene overexpression induces chemotherapy resistance in triple-negative breast cancer cells[J]. Electronic Journal of Metabolism and Nutrition of, 2019, 6(3): 310-315. |
| [2] |
ZHOU Yong， ZHENG Jin-ying， XU Xiao-hua， JIN Xiao-ling. Ampelopsin induces cell growth inhibition in breast cancer cells by suppressing pyruvate kinase M2-dependent glycolysis[J]. Electronic Journal of Metabolism and Nutrition of, 2019, 6(2): 236-241. |
| [3] |
1JIN Zhi-guo,?2ZENG Hui-jun . Influence of CYP4502E1 gene polymorphism on chemotherapeutic efficacy of recurrent breast cancer[J]. Electronic Journal of Metabolism and Nutrition of, 2019, 6(1): 58-61. |
| [4] |
1WU Jiang-ping, 2SUN Xiao-tong 3WANG Jingn 1LI Yu-chen,4ZHAO Lin. Clinical characteristics and treatment status of breast cancer in aged women[J]. Electronic Journal of Metabolism and Nutrition of, 2018, 5(4): 387-390. |
| [5] |
WANG Qian, SONG Ying, LI Er-ni, LIANG Yuan, LI Jing, ZHOU Chun-wu, ZHAO Xin-ming. Evaluation and analysis of psychological health status and psychological needs in young breast cancer patients[J]. Electronic Journal of Metabolism and Nutrition of, 2018, 5(2): 194-197. |
| [6] |
. A meta-analysis of clinical characteristics of breast cancer patients with
type-2 diabetes mellitus in Mainland China[J]. Electronic Journal of Metabolism and Nutrition of, 2015, 2(4): 35-42. |
|
|
|
|
